yl23455永利官网

    洞察市场格局
    解锁药品研发情报

    免费客服电话

    18983288589
    医药数据查询

    【ChiCTR2000028999】Early detection of dementia in subjects with type 2 diabetes based on white matter hyperintensities estimated by automatic retinal image analysis (ARIA) method

    基本信息
    登记号

    ChiCTR2000028999

    试验状态

    尚未开始

    药物名称

    /

    药物类型

    /

    规范名称

    /

    首次公示信息日的期

    2020-01-11

    临床申请受理号

    /

    靶点

    /

    适应症

    癡呆症

    试验通俗题目

    Early detection of dementia in subjects with type 2 diabetes based on white matter hyperintensities estimated by automatic retinal image analysis (ARIA) method

    试验专业题目

    Early detection of dementia in subjects with type 2 diabetes based on white matter hyperintensities estimated by automatic retinal image analysis (ARIA) method

    申办单位信息
    申请人联系人
    申请人名称
    联系人邮箱
    联系人邮编

    联系人通讯地址
    临床试验信息
    试验目的

    1. Validate and fine-tune the estimate of ARIA-WMH using MRI as gold standard. We will offer a MRI scan for the control subjects who have ARIA-WMH values falling on the top 10%-15% range (n=150). We will also randomly select 10%-15% subjects from the rest of the control group for comparison and evaluate the accuracy of the ARIA-WMH estimates as compared to the MRI values (n=150); 2. Estimate the grade and volume of white matter hyperintensities (WMH) using the automatic retinal image analysis (ARIA) method for both type 2 diabetes and control subjects. Compare the mean and proportions of grade 3 WMH among the two type 2 diabetes groups (both Hong Kong and UK) and the control group; 3. In the two diabetes groups, evaluate if there are significant associations between WMH and risks of other diabetic complications, including stroke, coronary heart disease, chronic kidney disease, and neuropathy.

    试验分类
    试验类型

    析因分组（即根据危险因素或暴露因素分组）

    试验分期

    其它

    随机化

    Nil

    盲法

    N/A

    试验项目经费来源

    ITF GRANT

    试验范围

    /

    目标入组人数

    1000;2000

    实际入组人数

    /

    第一例入组时间

    2020-01-15

    试验终止时间

    2022-07-31

    是否属于一致性

    /

    入选标准

    Aged >=18 years; Objective 1: Type 2 diabetes patients from Diabetic Eye Screening Wales (DESW) in United Kingdom and already took retinal images; Objective 2: Type 2 diabetes patients from the Risk Assessment and Management Programme (RAMP) in Hong King and already took retinal images; Control group: Willing to sign the informed consent form; Willing to comply with procedures required in the protocol.；

    排除标准

    Poor retinal images quality that cannot be used; Control group only: Subjects with other eye diseases which are not suitable for retinal imaging, such as severe cataract, glaucoma, atretopsia, corneal plague. Subjects are distress with flashlight or have experience with photosensitive seizure.；

    研究者信息
    研究负责人姓名
    试验机构

    The Centre for Clinical Research and Biostatistics, The Chinese University of Hong Kong

    研究负责人电话
    研究负责人邮箱
    研究负责人邮编

    /

    联系人通讯地址

    香港中文大學的其他临床试验

    更多

    最新临床资讯

    yl23455永利官网企业版
    50亿+条医药数据随时查
    7天免费试用
    体验产品